The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6

Free Radical Research

Volumn 44, Issue 11, 2010, Pages 1304-1316

  Niranjan, Rituraj ^a   Nath, Chandishwar ^a   Shukla, Rakesh ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

melatonin; MPTP; Neuroinflammation; NF B activation; Parkinson's disease; rat astrocytoma cells (C6)

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CALCIUM ION; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELATONIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOAMINE OXIDASE INHIBITOR;

ANIMAL CELL; ARTICLE; ASTROCYTOMA CELL; ASTROCYTOSIS; CALCIUM CELL LEVEL; ENCEPHALITIS; GENE; MODULATION; NITRATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; UPREGULATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ASTROCYTES; ASTROCYTOMA; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MELATONIN; NEUROTOXINS; NF-KAPPA B; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

RATTUS;

EID: 77957943337     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2010.501080     Document Type: Article

References (65)

1. Speciale SG. MPTP: insights into parkinsonian neurodegen-eration. Neurotoxicol Teratol 2002;24:607-620.
2. Emborg ME. Nonhuman primate models of Parkinson's disease. Ilar J 2007;48:339-355.
3. Campos-Romo A, Ojeda-Flores R, Moreno-Briseno P, Fernandez-Ruiz J. Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the HALLWAY task. J Neurosci Methods 2009;177:361-368.
4. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic signifi cance. Ann N Y Acad Sci 2008;1147:93-104.
5. Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, Czlonkowski A, Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 1998;39:167-180.
6. Nagatsu T, Sawada M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. J Neural Transm Suppl 2006;71:53-65.
7. Hu X, Zhang D, Pang H, Caudle WM, Li Y, Gao H, Liu Y, Qian L, Wilson B, Di Monte DA, Ali SF, Zhang J, Block ML, Hong JS. Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegenera-tion in the MPTP model of Parkinson's disease. J Immunol 2008;181:7194-7204.
8. Schneider JS, Denaro FJ. Astrocytic responses to the dopamin-ergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrid-ine (MPTP) in cat and mouse brain. J Neuropathol Exp Neurol 1988;47:452-458.
9. McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord 2008;23:474-483.
10. Karunakaran S, Ravindranath V. Activation of p38 MAPK in the substantia nigra leads to nuclear translocation of NF-kappaB in MPTP-treated mice: implication in Parkinson's disease. J Neurochem 2009;109:1791-1799.
11. Zhang W, Stanimirovic D. Current and future therapeutic strategies to target infl ammation in stroke. Curr Drug Targets Infl amm Allergy 2002;1:151-166.
12. Carbone DL, Moreno JA, Tjalkens RB. Nuclear factor kappa-B mediates selective induction of neuronal nitric oxide synthase in astrocytes during low-level infl ammatory stimulation with MPTP. Brain Res 2008;1217:1-9.
13. Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand Suppl 1983; 95:57-80.
14. Foley P, Gerlach M, Youdim MB, Riederer P. MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat Disord 2000;6:25-47.
15. Muramatsu Y, Kurosaki R, Watanabe H, Michimata M, Matsubara M, Imai Y, Araki T. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice. Glia 2003;42:307-313.
16. Reiter RJ. Melatonin: the chemical expression of darkness. Mol Cell Endocrinol 1991;79:153-158.
17. Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxifi cation to radical avoidance. Endocrine 2005;27:119-130.
18. Reiter RJ, Tan DX, Cabrera J, D'Arpa D, Sainz RM, Mayo JC, Ramos S. The oxidant/antioxidant network: role of melatonin. Biol Signals Recept 1999;8:56-63.
19. Mayo JC, Sainz RM, Tan DX, Hardeland R, Leon J, Rodriguez C, Reiter RJ. Anti-infl ammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol 2005;165:139-149.
20. Anderson G, Noorian AR, Taylor G, Anitha M, Bernhard D, Srinivasan S, Greene JG. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease. Exp Neurol 2007;207:4-12.
21. Lin CH, Huang JY, Ching CH, Chuang JI. Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats. J Pineal Res 2008;44:205-213.
22. Chuang JI, Chen TH. Effect of melatonin on temporal changes of reactive oxygen species and glutathione after MPP(+) treatment in human astrocytoma U373MG cells. J Pineal Res 2004;36:117-125.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
24. Martinez J, Sanchez T, Moreno JJ. Regulation of prostaglandin E2 production by the superoxide radical and nitric oxide in mouse peritoneal macrophages. Free Radic Res 2000; 32:303-311.
25. Colado MI, O'Shea E, Granados R, Msra A, Murray TK, Green AR. A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol 1997;121:827-833.
26. Anderson ME, Greenwald RA. Handbook of methods for oxygen radical research. CRC Press;(FL, USA). 1985.
27. Grynkiewicz G, Poenie M, Tsien RY A new generation of Ca2+ indicators with greatly improved fl uorescence properties. J Biol Chem 1985;260:3440-3450.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
29. Aoki E, Yano R, Yokoyama H, Kato H, Araki T Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahyropyridine)-induced apoptosis in nigral neurons of mice. Exp Mol Pathol 2009;86:57-64.
30. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999;5:1403-1409.
31. Scolari G, Lazzarin F, Fornaseri C, Carbone V, Rengo S, Amato M, Cicciu D, Braione D, Argentino S, Morgantini A, Bassetti C, Tramer M, Monza GC. A comparison of nimesulide beta cyclodextrin and nimesulide in postoperative dental pain. Int J Clin Pract 1999;53:345-348.
32. Miller RL, James-Kracke M, Sun GY, Sun AY. Oxidative and infl ammatory pathways in Parkinson's disease. Neurochem Res 2009;34:55-65.
33. Eng LF, Ghirnikar RS, Lee YL. Glial fi brillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 2000; 25:1439-1451.
34. Itano Y, Kitamura Y, Nomura Y 1-Methyl-4-phenylpyridinium (MPP+)-induced cell death in PC12 cells: inhibitory effects of several drugs. Neurochem Int 1994;25:419-424.
35. Friedman L, Mytilineou C. The toxicity of MPTP to dopamine neurons in culture is reduced at high concentrations. Neurosci Lett 1987;79:65-72.
36. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fl uid from parkinsonian patients. Neurosci Lett 1994;165:208-210.
37. Song X, Perkins S, Jortner BS, Ehrich M. Cytotoxic effects of MPTP on SH-SY5Y human neuroblastoma cells. Neurotoxicology 1997;18:341-353.
38. Yokoyama H, Kuroiwa H, Yano R, Araki T. Targeting reactive oxygen species, reactive nitrogen species and infl ammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci 2008;29:293-301.
39. Drechsel DA, Patel M. Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radic Biol Med 2008;44:1873-1886.
40. Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, Bing G. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinfl ammation 2006;3:6.
41. Fukae J, Mizuno Y, Hattori N. Mtochondrial dysfunction in Parkinson's disease. Mtochondrion 2007;7:58-62.
42. Tapias V, Escames G, Lopez LC, Lopez A, Cama-cho E, Carrion MD, Entrena A, Gallo MA, Espinosa A, Acuna-Castroviejo D. Melatonin and its brain metabolite N(1)-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in parkinsonian mice. J Neurosci Res 2009;13;3002-3010.
43. Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol Med 2009;15:89-100.
44. Iuvone T, Esposito G, De Filippis D, Bisogno T, Petrosino S, Scuderi C, Di Marzo V, Steardo L. Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro . J Mol Med 2007;85:1379-1392.
45. Blandini F, Bazzini E, Marino F, Saporiti F, Armentero MT, Pacchetti C, Zangaglia R, Martignoni E, Lecchini S, Nappi G, Cosentino M. Calcium homeostasis is dysregulated in parkinsonian patients with L-DOPA-induced dyskinesias. Clin Neuropharmacol 2009;32:133-139.
46. Zhou YT, Yang JF, Zhang YL, Wang XY, Chan P. Protective role of interlekin-1 alpha gene polymorphism in Chinese Han population with sporadic Parkinson's disease. Neurosci Lett 2008;445:23-25.
47. Parish CL, Finkelstein DI, Tripanichkul W, Satoskar AR, Drago J, Horne MK. The role of interleukin-1, interleukin-6, and glia in inducing growth of neuronal terminal arbors in mice. J Neurosci 2002;22:8034-8041.
48. Hofmann KW, Schuh AF, Saute J, Townsend R, Fricke D, Leke R, Souza DO, Portela LV, Chaves ML, Rieder CR. Interleukin-6 serum levels in patients with Parkinson's disease. Neurochem Res 2009;34:1401-1404.
49. Muller T, Blum-Degen D, Przuntek H, Kuhn W. Interleukin-6 levels in cerebrospinal fl uid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand 1998;98:142-144.
50. Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofrj M. Peripheral cytokines profi le in Parkinson's disease. Brain Behav Immun 2009;23: 55-63.
51. Bian MJ, Li LM, Yu M, Fei J, Huang F. Elevated interleukin-1beta induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-dine aggravating dopaminergic neurodegeneration in old male mice. Brain Res 2009;1302:256-264.
52. Zhao C, Ling Z, Newman MB, Bhatia A, Carvey PM. TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol Dis 2007;26:36-46.
53. de la Rocha N, Rotelli A, Aguilar CF, Pelzer L. Structural basis of the anti-infl ammatory activity of melatonin. Arznei-mittelforschung 2007;57:782-786.
54. Gilad E, Wong HR, Zingarelli B, Virag L, O'Connor M, Salzman AL, Szabo C. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation. Faseb J 1998;12:685-693. (Pubitemid 28247147)
55. Cui P, Yu M, Luo Z, Dai M, Han J, Xiu R, Yang Z. Intracel-lular signaling pathways involved in cell growth inhibition of human umbilical vein endothelial cells by melatonin. J Pineal Res 2008;44:107-114.
56. Schmitt-Ney M, Habener JF. CHOP/GADD153 gene expression response to cellular stresses inhibited by prior exposure to ultraviolet light wavelength band C (UVC). Inhibitory sequence mediating the UVC response localized to exon 1. J Biol Chem 2000;275:40839-40845.
57. Silva RM, Ries V, Oo TF, Yarygina O, Jackson-Lewis V, Ryu EJ, Lu PD, Marciniak SJ, Ron D, Przedborski S, Kholodilov N, Greene LA, Burke RE. CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J Neurochem 2005;95:974-986.
58. Esposito E, Iacono A, Muia C, Crisafulli C, Mattace Raso G, Bramanti P, Meli R, Cuzzocrea S. Signal transduction pathways involved in protective effects of melatonin in C6 glioma cells. J Pineal Res 2008;44:78-87.
59. Oktem G, Uslu S, Vatansever SH, Aktug H, Yurtseven ME, Uysal A. Evaluation of the relationship between inducible nitric oxide synthase (iNOS) activity and effects of melatonin in experimental osteoporosis in the rat. Surg Radiol Anat 2006;28:157-162.
60. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 2003;100:5473-5478.
61. Nogawa S, Zhang F, Ross ME, Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997;17:2746-2755.
62. Capitelli C, Sereniki A, Lima MM, Reksidler AB, Tufi k S, Vital MA. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats. Eur J Pharmacol 2008;594:101-108.
63. Hu J, Akama KT, Krafft GA, Chromy BA, Van Eldik LJ. Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res 1998;785:195-206.
64. Thiffault C, Lamarre-Theroux L, Quirion R, Poirier J. L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse. Brain Res Mol Brain Res 1997;44:238-244.
65. Muralikrishnan D, Samantaray S, Mohanakumar K P. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- induced dopaminergic neurotoxicity. Synapse 2003;50:7-13.